DermSafe is a patented hand sanitizer, formulated with 4% chlorhexidine gluconate, an active ingredient used internationally as a pre-surgical scrub and in periodontal products.
Skinvisible and RHEI claimed that DermSafe is made without alcohol, and is proven to kill both bacteria and viruses for up to four hours, even with hand washing.
The agreement follows the previously announced July 13 licensing agreement with RHEI for three skincare products, including an adult incontinence cream, barrier cream, and super moisturizer.
The agreement includes licensing fees payable in milestones based on regulatory approval in Europe and China, anticipated to occur within twelve months or less.
Under the contract, RHEI is expected to pay Skinvisible a royalty on product sales and be responsible for seeking regulatory approval, manufacturing, and commercialisation.
Skinvisible will retain rights to DermSafe for the retail/consumer markets within Europe and China. The agreement also provides Skinvisible with all data generated by RHEI to pursue regulatory approvals within the US and internationally.
Terry Howlett, president and CEO of Skinvisible, said: “These two new agreements with RHEI represent $1.5m in licensing fees and on-going royalties on product sales for Skinvisible.”